ImClone

(redirected from IMCL)
Also found in: Acronyms.

ImClone

A former publicly-traded company specializing in biotechnology, particularly the development of drugs treating cancer. It is known for the insider trading scandal involving its CEO, Sam Waksal, and television personality Martha Stewart. Both served time in federal prison for attempting (Waksal) or conducting (Stewart) insider trading. Since November 2008, ImClone has been a wholly-owned subsidiary of Eli Lilly and Company. Prior to its acquisition, ImClone was traded on NASDAQ.
Mentioned in ?
References in periodicals archive ?
According to Jess Jessop, CEO of IMCL, "Our customers are in a sector of the healthcare industry where there has to be zero tolerance for identity fraud.
The impact that Herceptin has had on Genentech underscores what we believe the market could eventually reflect into IMCL via C225.
Prior to today's trading, Schaeffer's put/call open interest ratio (SOIR) for IMCL weighed in at 0.
Pessimism toward a poorly performing stock should come as no surprise, and there isn't much in the way of warm feelings toward IMCL.
Click the following link to see a Monthly Chart of IMCL Since June 2004 With 10-Day Moving Average: http://www.
IMCL is slated to release its own earnings report on Wednesday, July 26.
Turning to the technical picture, we find that despite today's surge higher, IMCL remains mired in a long-term downtrend.